Clinical assessment of the optic nerve and retinal nerve fiber layer
Examination and documentation of the optic disc and retinal nerve fiber layer (RNFL) is essential for diagnosis and monitoring of glaucoma. With a high-power convex lens and stereoscopic slit lamp biomicroscopy, a clinician can observe and document the salient characteristics of glaucomatous optic neuropathy and identify subtle structural changes consistent with progression.
Clinical features including focal or diffuse narrowing of the neuroretinal rim width and loss of peripapillary RNFL, increased vertical excavation of the optic cup, presence of beta-zone parapapillary atrophy, and optic disc hemorrhage must be identified. Annotated detailed drawings 2. Disc size. Measurement of optic disc size is critical in order to interpret clinical estimates of cup-disc ratio and neural rim integrity. 6, 7 Large optic discs have physiologic increased cupping that may be confused with glaucoma; small glaucomatous discs may not manifest any appreciable cupping or neural rim atrophy. 8 Optic disc size may be clinically estimated using a slit lamp reticule. Such measurements have limited reproducibility and can be affected (particularly at the extremes) by axial length, refractive error, and magnification. Quantitative imaging provides a useful means of quantifying optic disc size. Although the measurements may differ across technologies 9 , such measurements are highly reproducible and facilitate the interpretation of the optic disc in common clinical situations such as a glaucoma suspect with enlargement of cup-disc ratio due to a physiologically large macrodisc, or cup-disc asymmetry between fellow eyes due to asymmetry in disc area. 
Standard Structural Endpoints in Glaucoma Clinical Trials
The standard structural efficacy endpoint in randomized and population-based glaucoma clinical trials is a reproducible change in optic disc appearance using stereoscopic optic disc photography 12,
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With careful inspection, glaucomatous structural progression may be identified by noting diffuse or focal neural rim thinning with expansion of the optic cup, and progressive RNFL atrophy.
Non-quantitative changes such as optic disc pallor, parapapillary atrophy, and optic disc In the OHTS, inspection of disc photographs identified significantly more frequent disc hemorrhage events than recorded by the examiner. 35 There are limitations to using optic disc photography as the sole structural outcome measure in glaucoma clinical research. Glaucoma progression occurs slowly and changes are often subtle and easily missed. Further, fewer optic disc endpoints exists in eyes with moderately advanced glaucoma with considerable neural rim atrophy complicating the ability to detect structural change.
In ocular hypertensive eyes with normal optic disc appearance enrolled in the European Glaucoma Prevention Study (EGPS) and OHTS, isolated optic disc endpoints were observed in 40% 36 and 55% 31 of progressing eyes respectively. In contrast, 0.8% and 11% of progressing eyes with established glaucomatous optic nerve damage demonstrated detectable structural endpoints in the Early Manifest Glaucoma Trial (EMGT) 32 and Collaborative Normal-Tension Glaucoma Study 33 , respectively. Unresolved issues exist regarding viewing methods and confirmation of suspected structural progression that may have contributed to these discrepant results. In the OHTS confirmatory optic disc photographs were required to substantiate suspected change and direct stereo-viewing of images by experts was utilized to assess optic disc progression. In EGPS 30 confirmatory disc photographs were not obtained, and in the EMGT 37 flicker chronoscopy of non-stereo disc images, but not stereoscopic disc photography, was utilized to assess optic disc progression.
Role of Imaging in Clinical Trials
Imaging technologies have the potential to identify relevant structural efficacy endpoints in randomized clinical trials (RCTs). The HRT has been studied in the EGPS 36 and in an ancillary study of the OHTS 38 . Topographic parameters generated with the HRT have been demonstrated to correlate highly with clinical estimates of the optic nerve generated using expert assessment at an independent reading center after correction for optic disc size. 39 The CSLO ancillary study to the OHTS 38 demonstrated that the HRT may predict conversion to primary open-angle glaucoma with a positive predictive power of up to 40%, and a negative predictive power of 93%. Thus far, glaucoma RCTs have not employed RNFL imaging technologies such as OCT or GDxVCC. It is highly probable, however, that RNFL assessment will play an expanded role in trials to explore both IOP-lowering and non-IOP lowering therapies such as potential neuroprotective compounds in which the optic disc and RNFL is a more appropriate efficacy endpoint.
Imaging is unlikely to replace optic disc photography in glaucoma RCTs or clinical practice, nor should it. Optic disc photographs are a useful means of judging progression, particularly in glaucoma suspects and eyes with early disc damage, and documentation of optic disc hemorrhage.
Yet, imaging may serve as a useful adjunct to disc photography to provide complementary information that may facilitate progression detection using rate-based changes over time since the output data is quantitative, and highly reproducible at all stages of the glaucoma continuum.
Imaging in RCTs may also be useful for enrichment of glaucoma cohorts consisting of populations at high risk for glaucoma progression. For example, ocular hypertensive eyes with baseline HRT abnormalities 38 and reduced RNFL thickness measured with OCT 14 and GDx 13 have been demonstrated to be at increased risk for subsequent progression to POAG. Finally, imaging may provide an opportunity for more robust identification of glaucoma endpoints and faster, less costly clinical trials. Regulatory hurdles presently exist that limit the ability to use optic disc and RNFL imaging as endpoints.
Pitfalls With Imaging
Technology undergoes constant evolution and we as physicians, and our patients, have benefited considerably in this regard. The last decade has produced expansion of datasets that enable one to differentiate normal from abnormal, improved precision, increased resolution and image registration; and constant software upgrades. A sacrifice for such change has been the costs associated with replacing technologies that become outdated or are no longer backwards compatible with previously collected data. This has certainly negatively impacted longitudinal studies seeking to validate the use of imaging for detection of glaucoma progression. Other pitfalls exist. Image quality is dependent upon operator skill, patient-related factors such as pupil diameter and media clarity, and instrument-dependent variables. Imaging artifact, such as poorly compensated corneal birefringence using the GDx [40] [41] [42] [43] [44] or the low signal strength using the OCT that is sometimes identified 45, 46 , continues to exist amongst all technologies prompting questions regarding the precise role of imagers in clinical practice. 47 Imaging may produce false identification of glaucoma and its progression. Imaging also may fail to detect a glaucomatous optic disc or RNFL. E. Acknowledgements: None.
